Clinical trials
HER 2 Negative Breast Cancer clinical trials
Below are recruiting her 2 negative breast cancer clinical trials, each written for real people, not researchers. We’re tracking 930 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07563595Recruiting
Elacestrant for advanced ER+ HER2- breast cancer with ESR1 mutation
This trial tests elacestrant, a new hormone therapy drug, in women whose advanced or spread breast cancer has stopped responding to first-line hormone treatment. The drug is designed to work against a specific genetic change (ESR1 mutation) that can develop in these cancers.
Freiburg im BreisgauAges 18 years+ - NCT07579286Recruiting
Skipping lymph node surgery in early breast cancer
This trial tests whether older women with early-stage, slow-growing breast cancer can safely skip removal of underarm lymph nodes during surgery. The goal is to reduce surgery-related side effects while maintaining safety.
Saint Petersburg, Russian FederationAges 60 years+ - NCT07586826RecruitingPhase 2
Romiplostim N01 plus ATRA for low platelets after cancer treatment
This trial tests a combination of two drugs (romiplostim N01 and ATRA) to help raise platelet counts in people whose platelets dropped after chemotherapy for gynecologic, breast, or lung cancer—even though their cancer is now gone. Low platelets can cause bleeding problems, so this treatment aims to help your body make more platelets.
BeijingAges 18 years+ - NCT07601178RecruitingPhase 2
Immunotherapy and targeted drugs for advanced triple-negative breast cancer
This trial tests a combination of four drugs—two immunotherapies (QL1706), an anti-angiogenic agent (anlotinib), and chemotherapy (nab-paclitaxel)—as a first-line treatment for advanced triple-negative breast cancer. The goal is to see if this combination slows or stops cancer growth better than standard treatment alone.
Nanjing, JiangsuAges 18–75 - NCT07612891RecruitingPhase 1/Phase 2
Testing INV-6452 for advanced breast cancer and solid tumors
This study tests a new drug called INV-6452 to see if it is safe and can help control advanced cancers that have grown despite prior treatment. The drug targets specific cancer cell weaknesses, particularly in hormone-sensitive breast cancers without HER2 mutations.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07646106RecruitingPhase 1
Testing THE-0504 in Advanced Solid Tumors
This Phase 1 trial tests a new drug called THE-0504 in patients with advanced solid tumors (like lung, colon, pancreas, stomach, or breast cancer) that have not responded to standard treatments. The study aims to find the right dose and understand how well and safely the drug works.
Rome, LazioAges 18 years+ - NCT07647016RecruitingPhase 2
New Drug Combination for Advanced Hormone-Receptor-Positive Breast Cancer
This study tests two drugs together—trastuzumab deruxtecan and ivonescimab—for advanced breast cancer that is hormone-receptor-positive but HER2-negative or HER2-low. These drugs work by targeting cancer cells in different ways and may help slow or shrink tumors in patients whose cancer has progressed after earlier treatments.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07657130RecruitingPhase 2
Timing of ADC drug for advanced breast cancer
This trial is testing the best time to give an antibody-drug conjugate (ADC) to people with advanced breast cancer that is HER2-negative. It aims to find out if giving this treatment after first chemotherapy fails can help slow the cancer's growth.
Shenyang, LiaoningAges 18–75 - NCT07666555RecruitingPhase 2
Culmerciclib rechallenge for HR+ HER2- breast cancer
This trial tests a new drug called Culmerciclib for women with advanced HR-positive, HER2-negative breast cancer that has stopped responding to a CDK4/6 inhibitor with hormone therapy. The goal is to see if giving this drug again can help when other treatments no longer work.
ShanghaiAges 18–75 - NCT07669467RecruitingPhase 3
Nuvastatic for fatigue in triple-negative breast cancer patients
This trial tests whether Nuvastatic, a natural supplement, can help reduce fatigue in women with triple-negative breast cancer who are about to start chemotherapy. If you have stable or worsening fatigue and meet the other criteria, you may be able to join.
Visakhapatnam, Andhra PradeshAges 18–65 - NCT07275463Enrolling by invitationPhase 2
Study of DB8 imaging in estrogen receptor positive and negative breast cancer
This trial uses a special imaging agent called DB8 to see how it builds up in breast tumors. It compares results between women with estrogen receptor-positive and estrogen receptor-negative cancers to help improve detection.
TomskAges 18–80 - NCT07218003Enrolling by invitationPhase 1
Study of RNDO-564 alone or with pembrolizumab for bladder cancer
This trial tests an experimental drug, RNDO-564, either by itself or combined with another drug (pembrolizumab), for people with advanced bladder cancer or other solid tumors that have stopped responding to standard treatments. The goal is to see if it can shrink tumors or slow cancer growth.
San Francisco, CaliforniaAges 18 years+ - NCT06890871Enrolling by invitationPhase 1/Phase 2
Radiation with immunotherapy and anti-angiogenic therapy for advanced HER2-negative breast cancer
This trial tests a combination of radiation therapy, immunotherapy, and a drug that blocks blood vessel growth for advanced HER2-negative breast cancer that has spread. It is for patients whose cancer has worsened after at least two prior treatments.
Wuhan, HubeiAges 18–75 - NCT06885424Enrolling by invitation
Long-term follow-up for A2 Bio gene therapy patients
This study follows up with people who previously received a gene therapy product from A2 Biotherapeutics in an earlier trial. The goal is to monitor their health over time and check for any long-term effects.
Gilbert, ArizonaAges 18 years+ - NCT06650748Enrolling by invitationPhase 2
A study of hormone therapy with or without a targeted drug for breast cancer
This trial tests if adding a targeted drug (CDK4/6 inhibitor) to hormone therapy works better than hormone therapy alone for women with a certain type of breast cancer (HR+/HER2-). The study measures the activity of tumor cells (Ki-67) to help decide treatment.
BeijingAges 18–70 - NCT05827081RecruitingPhase 3
Ribociclib plus endocrine therapy for early breast cancer
This trial studies whether adding ribociclib to standard hormone (endocrine) therapy lowers the risk of breast cancer coming back in early-stage, hormone-receptor–positive cancer. It mainly looks at safety and how well the treatment controls cancer after surgery and (sometimes) prior hormone treatment.
Birmingham, AlabamaAges 18–100 - NCT07524855RecruitingPhase 1
HLD-0117 study for metastatic breast cancer
This early-stage study tests a new drug called HLD-0117 in women whose metastatic breast cancer (cancer that has spread beyond the breast) has stopped responding to previous hormone and targeted therapies. The goal is to see if this drug can slow or shrink the cancer in patients who have limited options left.
New Haven, ConnecticutAges 18 years+ - NCT02102165Recruiting
Study samples from metastatic triple-negative breast cancer
This study looks at tumor “clues” by using tissue and blood samples in people with metastatic breast cancer (with specific subtype). It aims to better understand what drives the cancer, which may help guide future treatments.
BrusselsAges 18 years+ - NCT06176534RecruitingPhase 2
Comparing two treatments for advanced breast cancer with low hormone receptor
This trial compares two treatment options for advanced breast cancer that has low hormone receptor levels and is HER2-negative. It tests whether a combination of chemotherapy followed by maintenance therapy works better than a CDK4/6 inhibitor combined with hormone therapy. This is for people who have not had chemotherapy for their advanced disease.
Zhengzhou, HenanAges 18 years+ - NCT05505357Recruiting
Skip breast surgery after excellent MRI response
This trial tests whether some women with HER2-positive breast cancer can safely avoid breast surgery if their tumor nearly disappears after chemotherapy. It uses MRI and biopsy results to find people most likely to have no remaining cancer (pCR).
SeoulAges 20 years+ - NCT04680715RecruitingPhase 2
Tested radiation before and after breast surgery in older women
This Phase 2 trial looks at a specific radiation timing and technique around the time of breast-conserving surgery. It may help reduce the chance the cancer comes back in selected older patients with certain early-stage, hormone-positive, HER2-negative breast cancers.
Clermont-FerrandAges 65 years+ - NCT05530057RecruitingPhase 2
Eribulin plus or minus trastuzumab for HER2-positive breast cancer
This trial tests whether adding trastuzumab to eribulin improves outcomes for people with HER2-positive breast cancer that has come back or spread. It’s meant for patients whose cancer has progressed after prior HER2 and chemotherapy treatments.
SeoulAges 18 years+ - NCT07597629RecruitingPhase 2
SYS6023 combination therapy for advanced breast cancer
This trial tests a new drug combination (SYS6023) for advanced breast cancer that has spread or cannot be surgically removed. The treatment targets a protein called HER3, which may help stop cancer growth in patients whose cancer has progressed despite previous treatments.
Harbin, HeilonjiangAges 18 years+ - NCT07591090RecruitingPhase 2
Drug combination study for advanced HER2-negative breast cancer
This study tests whether combining two new drugs (AK146D1 and AK112) can help people with advanced breast cancer that is HER2-negative (a type that doesn't have too much of a specific growth protein). The goal is to see if this combination can shrink tumors and improve survival.
Shanghai, Shanghai MunicipalityAges 18–75
Hear when a new HER 2 Negative Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for her 2 negative breast cancer?
- Yes. Clin2 currently lists 930 recruiting her 2 negative breast cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a her 2 negative breast cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a her 2 negative breast cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Breast Cancer (Triple Negative Breast Cancer (TNBC))
- Breast Cancer Early Stage Breast Cancer (Stage 1-3)
- Hormone Receptor Positive HER-2 Negative Breast Cancer
- HR Positive/HER-2 Negative Breast Cancer
- Triple Negative Breast Cancer
- HER2-negative Breast Cancer
- Metastatic Triple-negative Breast Cancer
- Advanced Triple Negative Breast Cancer
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.